Addressing these questions will allow better understanding of the role of the SMURF2–KAP1 complex in the biology of untransformed and malignant cells, promoting the development of pathway-oriented precision therapies targeting KAP1 in cancer. This evidence concerns the gene SMURF2 and cancer.